Pharming Group Competitors

Seer (NASDAQ:SEER) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Seer and Pharming Group's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Seer and Pharming Group, as reported by MarketBeat.com.

Seer currently has a consensus price target of $68.00, suggesting a potential upside of 30.79%. Given Seer's higher possible upside, equities research analysts clearly believe Seer is more favorable than Pharming Group.

Valuation and Earnings

This table compares Seer and Pharming Group's gross revenue, earnings per share and valuation.

Summary

Seer beats Pharming Group on 2 of the 2 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Valuation and Earnings

This table compares Nuvation Bio and Pharming Group's gross revenue, earnings per share and valuation.

Profitability

This table compares Nuvation Bio and Pharming Group's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Nuvation Bio and Pharming Group, as reported by MarketBeat.com.

Nuvation Bio currently has a consensus price target of $17.40, suggesting a potential upside of 74.00%. Given Nuvation Bio's higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than Pharming Group.

Summary

Nuvation Bio beats Pharming Group on 2 of the 2 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares ImmunityBio and Pharming Group's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares ImmunityBio and Pharming Group's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ImmunityBio and Pharming Group, as provided by MarketBeat.com.

ImmunityBio currently has a consensus target price of $25.00, suggesting a potential upside of 48.19%. Given ImmunityBio's higher possible upside, analysts plainly believe ImmunityBio is more favorable than Pharming Group.

Summary

ImmunityBio beats Pharming Group on 2 of the 2 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares BioAtla and Pharming Group's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares BioAtla and Pharming Group's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BioAtla and Pharming Group, as provided by MarketBeat.com.

BioAtla currently has a consensus target price of $58.00, suggesting a potential upside of 22.49%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Pharming Group.

Summary

BioAtla beats Pharming Group on 2 of the 2 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares Immunocore and Pharming Group's gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Immunocore and Pharming Group's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Immunocore and Pharming Group, as provided by MarketBeat.com.

Immunocore currently has a consensus target price of $54.3333, suggesting a potential upside of 53.18%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Pharming Group.

Summary

Immunocore beats Pharming Group on 2 of the 2 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Profitability

This table compares Cullinan Oncology and Pharming Group's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cullinan Oncology and Pharming Group, as provided by MarketBeat.com.

Cullinan Oncology currently has a consensus target price of $48.25, suggesting a potential upside of 49.38%. Given Cullinan Oncology's higher possible upside, analysts plainly believe Cullinan Oncology is more favorable than Pharming Group.

Earnings and Valuation

This table compares Cullinan Oncology and Pharming Group's gross revenue, earnings per share (EPS) and valuation.

Summary

Cullinan Oncology beats Pharming Group on 2 of the 2 factors compared between the two stocks.